<DOC>
	<DOCNO>NCT00089362</DOCNO>
	<brief_summary>This phase I trial study side effect best dose alvespimycin hydrochloride treat patient metastatic unresectable solid tumor . Drugs use chemotherapy , alvespimycin hydrochloride , work different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Alvespimycin Hydrochloride Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine toxic effect maximum tolerate dose 17-dimethylaminoethylamino-17-demethoxygeldanamycin ( 17-DMAG ) patient metastatic unresectable solid tumor . SECONDARY OBJECTIVES : II . Determine effect drug expression Hsp90 client protein normal tumor tissue sample patient . OUTLINE : This dose-escalation study . Patients receive alvespimycin hydrochloride IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 1-2 patient receive accelerate escalate dos alvespimycin hydrochloride least 1 2 patient experience dose-limiting toxicity ( DLT ) . Cohorts expand 3-6 patient receive escalate dos ( standard manner ) alvespimycin hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience DLT . Once MTD determine , 10 additional patient treat dose .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Carcinoma , Mucoepidermoid</mesh_term>
	<mesh_term>Esthesioneuroblastoma , Olfactory</mesh_term>
	<mesh_term>Papilloma , Inverted</mesh_term>
	<criteria>Histologically confirm solid tumor , include , limited , follow : Prostate Breast Ovary Colon Kidney Head neck Stomach Melanoma Metastatic unresectable disease No standard curative palliative therapy exist longer effective Progressive disease indicate follow : Nonprostate cancer New lesion increase preexist lesion bone scintigraphy , CT scan , MRI , physical examination No increase biochemical marker ( e.g. , carcinoembryonic antigen CA153 ) symptom sole evidence disease progression Prostate cancer Must castrate metastatic disease ( i.e. , disease progression castration treatment gonadotropinreleasing hormone [ GnRH ] analog ) Patients undergone surgical orchiectomy must continue medical therapy ( i.e. , GnRH analog ) maintain castrate level serum testosterone &lt; 50 ng/dL Patients receive antiandrogen part firstline hormonal therapy must show disease progression discontinue treatment Progressive metastatic disease image study ( e.g. , bone scan , CT scan , MRI ) OR metastatic disease rise prostatespecific antigen ( PSA ) allow Biochemical progression define minimum 3 rise PSA value baseline obtain least 1 week apart OR 2 rise PSA value obtain 1 month apart , &gt; = 25 % increase value No active brain metastasis Hormone receptor status : Not specify Male female Performance status Karnofsky 70100 % Performance status ECOG 01 More 6 month WBC &gt; = 3 , 000/mm^3 Absolute neutrophil count &gt; = 1 , 500/mm^3 Platelet count &gt; = 100,000/mm^3 Bilirubin = &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 1.5 time ULN PT normal Creatinine = &lt; 1.4 mg/dL Creatinine clearance &gt; 55 mL/min QTc &lt; 450 msec male patient ( 470 msec female patient ) LVEF &gt; 40 % MUGA No history serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation &gt; = 3 beat row ) No myocardial infarction within past year No active ischemic heart disease within past year No New York Heart Association class III IV congestive heart failure No congenital long QT syndrome No leave bundle branch block No poorly control angina No history uncontrolled dysrhythmias require antiarrhythmic drug Calcium blocker beta blocker allow No significant cardiac disease Oxygen saturation &gt; 88 % Dyspnea &lt; grade 2 rest room air No clinically significant pulmonary comorbidity ( e.g. , severe chronic obstructive pulmonary disease ) No requirement supplemental oxygen Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active ongoing infection No symptomatic peripheral neuropathy &gt; = grade 2 No psychiatric illness social situation would preclude study compliance No uncontrolled illness More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) At least 1 week since prior ketoconazole More 4 week since prior radiotherapy Recovered prior therapy More 4 week since prior investigational anticancer therapeutic drug No concurrent combination antiretroviral therapy HIVpositive patient No concurrent administration follow herbal remedy : Hydrastis canadensis ( goldenseal ) Hypericum perforatum ( St. John 's wort ) Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia root Trifolium pratense ( wild cherry ) Matricaria chamomilla ( chamomile ) Glycyrrhiza glabra ( licorice ) Dillapiol Hypericin Naringenin No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>